Delphinus Venture Capital

Delphinus Venture Capital is a Danish investment firm dedicated to backing research-driven startups that address significant global challenges. The firm focuses on scalable, deep tech solutions with strong defensibility across key verticals, including Food & Agriculture, Health & Longevity, Defense & Security, and Energy & Bioeconomy. They seek companies developing innovative software and AI with proprietary data, hardware with outsourced manufacturing, biotechnology with robust intellectual property, and enabling technologies that accelerate R&D in deep tech. The firm explicitly avoids business models reliant on high capital expenditure, low margins, limited defensibility, foundational AI models, capital-intensive manufacturing, or consumer products competing primarily on price.

Launched in 2025, Delphinus Venture Capital operates as an evergreen fund with €80 million in capital, providing a long-term perspective on value creation. The fund was established through a collaborative effort by four prominent limited partners: Aarhus University Research Foundation, Salling Group, Norlys, and Heartland. Based in Aarhus, Denmark, the firm maintains close proximity to leading research environments such as Aarhus University and Aarhus University Hospital, aiming to bridge the 'valley of death' for deep tech startups. Mathias Brink Lorenz was appointed as the fund's CEO and director, bringing international venture capital experience to the role.

The firm's portfolio showcases a diverse range of innovative companies transforming various sectors. Notable investments include Decameal, a foodtech company valorizing invasive shore crabs into sustainable protein; EtOH Spirits, which develops technology to accelerate spirit maturation; MedicQuant, a MedTech firm creating rapid diagnostics for acute stroke care; and Kvantify, a deep-tech company advancing drug discovery through computational software. Other portfolio companies include Reduced, focusing on natural savory ingredients; LevitaCare, a MedTech device for postpartum pelvic floor support; Ora Biotics, developing prebiotic ingredients; Cystotech, with AI-based bladder cancer diagnostics; and Cordulus, providing hyper-local weather forecasts.

The Delphinus Venture Capital team is characterized by a blend of experience, network, and dedication, coupled with a genuine curiosity for the founders and their ideas. They are committed to supporting passionate entrepreneurs who aim to translate research into tangible impact. The team, including CEO Mathias Brink Lorenz, leverages their venture capital expertise, scientific insight, and operational understanding to provide strategic guidance, network access, and mentorship, assisting startups in refining products, entering markets, and scaling efficiently.